Beta-TCP Graft Material With Chimeric Polypeptide for Bone Repair

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current methods for treating large or segmental bone defects, such as bone grafting, face limitations including donor site pain, risk of rejection, limited donor supply, and poor tissue regrowth due to loss of implanted progenitor cells and inadequate regeneration on orthopedic substrates.

Innovation Solution

The use of a composition comprising β-tricalcium phosphate (β-TCP) and a chimeric polypeptide with β-TCP binding sequences and a mammalian growth factor, like BMP-2, to enhance bone healing by increasing and sustaining progenitor cells at injury sites through stem cell capture and improved tissue regeneration.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If bone grafting is used to treat large or segmental bone defects, then bone repair can be achieved, but donor site pain, risk of rejection, limited donor supply, and risk of transmission of infectious disease occur

Engineering Contradiction:

Improvebone repair effectivenessVSAvoiddonor site pain, rejection risk, infectious disease risk

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent uses β-TCP as an intermediary carrier material that delivers growth factors and captures progenitor cells at the defect site, replacing the need for donor bone tissue while achieving similar bone repair outcomes without the associated risks of donor site complications and rejection

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The invention creates a synthetic alternative (β-TCP with growth factors) that copies the essential bone-inducing properties of natural bone grafts without requiring actual bone tissue from donors, thereby eliminating donor-related complications while maintaining therapeutic effectiveness

Inventive Principle:

Principle #26Copying

2Strength

If orthopedic substrates are implanted for bone defect repair, then structural support is provided, but poor tissue regrowth occurs due to loss of implanted progenitor cells within 48 hours and scarcity of progenitor cells

Engineering Contradiction:

Improvestructural supportVSAvoidtissue regrowth effectiveness

Core Design Contradiction:

StrengthVSReliability

Solution Approach 1:

The patent replaces passive mechanical support substrates with an active biological system where β-TCP binds growth factors and captures progenitor cells through specific molecular interactions, transforming the substrate from a purely structural component to a biologically active platform that promotes tissue regeneration

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

Solution Approach 2:

The invention changes the surface properties of the implant by coating with β-TCP and incorporating growth factors, altering the biological parameters (cell adhesion, proliferation, differentiation) while maintaining the mechanical structural support function

Inventive Principle:

Principle #35Parameter changes

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

This approach significantly improves bone healing and tissue regrowth by maintaining progenitor cells, overcoming limitations of existing treatments by promoting effective bone or cartilage formation and repair.

Implementation Method 1

the chimeric polypeptide binds specifically to the graft material

Methodology Applied

Scientific EffectAdsorption: Adsorption

Data Source

PatentUS20230203115A1Therapeutic compositions comprising graft materials and beta-TCP binding peptides and uses thereof

Publication Date: 2023.06.29 THERADAPTIVE INC

AI summary

Provided herein are polypeptides that include one or more β-tricalcium phosphate (βTCP)-binding sequence(s) and uses thereof.